In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Quest Diagnostics trades 9% above its PERT-weighted fair value with high confidence, indicating potential overvaluation. Monte Carlo analysis reveals high volatility and downside risk (66.7%), despite an expected value near current levels. Valuation methods diverge sharply, reflecting uncertainty in growth and profit sustainability.